The invention provides application of a GSDMD inhibitor in preparation of a chronic obstructive
pulmonary disease (
COPD) treatment preparation, and relates to the technical field of biological medicines.The
COPD mouse model induced by
cigarette smoke is established and divided into a control group, a
COPD group and a COPD + inhibitor group (GS DMD inhibitor), and the GS DMD inhibitor and the COPD + inhibitor group (GS DMD inhibitor) are combined through methods of
Western Blot, ELISA, qPCR, a transmission
electron microscope and the like, so that the chronic obstructive
pulmonary disease (COPD) treatment preparation is obtained. And detecting GSDMD pathway related
protein and
gene expression, inflammatory factor release level and alveolar
barrier function change. A GSDMD channel in the COPD model group is obviously activated, which shows that the expression levels of GSDMD-N and
Caspase-1 are increased; the concentration of IL-1beta and IL-18 is obviously increased; the expression levels of NLRP3, ASC and pro-
Caspase-1 and the concentration of HMGB1 in BAL F are increased, the
alveolar epithelial cell structure is damaged, and the wet-to-dry ratio and the
total protein content are increased. The GSDMD inhibitor significantly reduces the above indexes and improves the
airway epithelial barrier function. It is determined that the GSDMD pathway aggravates the
airway epithelial
cell injury and
inflammatory response of COPD by inducing
pyroptosis. The GSDMD inhibitor can significantly inhibit
pyroptosis and improve COPD-related
pathological changes, and provides a new target and theoretical basis for treatment of COPD.